

# Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 11

**Date:** 05/05/2023

**Location:** Virtually via Zoom

Minutes: Confirmed

Committee members present:				
Alison Cameron (Chair)	(Present for notes 1 – 8)			
Ranjit Manchanda (Topic Advisor)	(Present for note 4)			
Rebecca Bowen	(Present for notes 1 – 8)			
Adam Brentnall	(Present for notes 1 – 8) (Present for notes 1 – 8) (Present for notes 1 – 8)			
Melanie Davies				
Judith Hayward				
Glenn McCluggage	(Present for notes 1 – 4)			
Tracie Miles	Present for notes 1 - 4 and 6 - 8)			
Davina Moses	(Present for notes 1 – 8)			
Fiona Robb	(Present for notes 1 – 8)			
Adam Rosenthal	(Present for notes 1 – 8)			
Lucy Side	(Present for notes 1 – 8)			
Joanne Stanford	(Present for notes 1 – 8)			
Mark Davies	(Present for notes 1 – 8)			
Britta Stordal	(Present for notes 1 – 8)			

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Nick O'Callaghan Staples	Guideline Commissioning Manager	(Present for notes 1 – 8)
Adam Storrow	Resource Impact Lead	(Present for notes 1 – 8)

Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 8)
Expert witness attendance		
Xia Wei, PhD student – London School of Hygiene and Tropical Medicine	(Present for items 1 - 4)	
Rosa Legood – Associate Professor of Health Economics - LSHTM	(Present for item 4)	

Apologies:	
Victoria Barber	Committee member
Gareth Evans	Committee member
Vishakha Tripathi	Committee member
Steve Pilling	Clinical Advisor
Neil Ryan	Clinical Fellow

## 1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members and attendees to the 11<sup>th</sup> meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives.

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared as noted below. Ranjit Manchanda was excluded from the morning discussion relating to topic 4.1 due to a conflict arising from previously declared interests.

Role	Type of	Description	Relevant dates			Comment
	interest	of interest				s
			Interest	Interest	Interest	
			arose	declared	ceased	
Topic Advisor	Direct non- financial profession al and personal interest	Chief investigator on PROTECT-C trial. Additional	15/04/202 3	10/05/202	Ongoing	Declare and participate.  Agreed by Committee Chair and
	Торіс	Topic Direct non-financial profession al and personal	Topic Advisor Direct non-financial profession al and personal prosession al and personal profession trial.	interest of interest  Interest arose  Topic Advisor  Direct non-financial profession al and personal personal  Direct non-financial investigator on PROTECT-C trial.	Topic Advisor Direct non-financial profession al and personal PROTECT-C trial.  Interest Interest declared  Interest 3  Interest 3  Interest 3  Interest 4  Interest 4  Interest 3  Interest 3  Interest 3  Interest 4  Interest 4  Interest 3  Interest 4  Interest 3  Interest 4  Interest 4  Interest 4  Interest 3  Interest 4  Interest 4  Interest 4  Interest 4  Interest 7  Interest 3  Interest 4  Interest 4  Interest 4  Interest 4  Interest 4  Interest 7  Interest 8  Interest 9  Intere	interest of interest Interest Interest declared ceased  Topic Advisor Direct non-financial profession al and personal PROTECT-C trial.  Interest Interest declared ceased  15/04/202 3 10/05/202 3 Ongoing

			from Yorkshire Cancer Research to QMUL for this study in April 2023				Lead May 2023  Rationale: This trial is ongoing and will not be finished before the guideline is published.
Dr Lucy Side	Committe e member	Direct financial interest	Invited speaker – Eli Lilly sponsored meeting "Hot Topics in Endocrinolog y"	19/05/202 3	25/05/202 3	19/05/202 3	Declare and participate.  Agreed by GL – May 2023  Rationale: This is not specific to the scope of the guideline.

The Chair introduced Nathan Bromham, Senior Systematic Reviewer, who gave an update on 8.2 pathological protocols and findings from updated searches.

### 3. Minutes of the last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.

#### 4. Morning presentations

The Chair introduced Eric Slade, Senior Health Economist, who presented the economic model for evidence review 4.1: 'At what carrier probability should people with a family history of cancer suggestive of pathogenic variants in ovarian cancer predisposition genes be offered genetic testing?'

The Chair introduced Suhayl Kassam, Systematic Reviewer and Joanne Stanford, 7.1 Topic Group Lead, who presented evidence review 7.1: 'How effective are preventive medicines for reducing the incidence of ovarian cancer for women at increased risk of familial ovarian cancer?'

The Chair introduced Expert Witnesses, Xia Wei, PhD student at LSHTM and Rosa Legood, Associate Professor of Health Economics at LSTHM, who presented the economic model for evidence review 8.1 (update): 'How effective is risk-reducing surgery for women at increased risk of familial ovarian cancer (also considering risk threshold, age and extent and types of surgery)?'

## 5. Lay member forum

Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.

## 6. Afternoon presentations

The Chair introduced Laura Berg, Systematic Reviewer and Melanie Davies, 8.3 Topic Group Lead who presented evidence review 8.3: 'What are the benefits and risks of hormone replacement therapy after risk-reducing surgery for women at increased risk of familial ovarian cancer?'

Katharina Dworzynski, Guideline Lead led a discussion on research recommendations.

#### 7. Questions and discussion

The committee discussed:

- The impact of the economic model for 4.1 on the draft recommendations.
- The evidence presented for 7.1 and drafted recommendations using topic group suggestions as a starting point. The committee discussed equality considerations and potential change in practice due to the recommendations and the resource impact this would have.
- The economic model for 8.1 and how this impacted on draft recommendations.
- The evidence for 8.3 and began drafting recommendations using topic group suggestions as stating points.
- The research recommendations and the order of these recommendations.

#### 8. Any other business and summary of actions

Katharina Dworzynski summarised the actions and confirmed the topics for the next meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

**Date of next meeting:** 02/06/2023 and 08/06/2023

**Location of next meeting:** Via Zoom.